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Purpose. To further validate the prognostic power of the biomarker PDE4D7, we investigated the correlation of PDE4D7 scores
adjusted for presurgical clinical variables with longitudinal postsurgical biological outcomes. Methods. RNA was extracted from
biopsy punches of resected tumors (550 patients; RP cohort) and diagnostic needle biopsies (168 patients; DB cohort). Cox
regression and survival were applied to correlate PDE4D7 scores with patient outcomes. Logistic regression was used to combine
the clinical CAPRA score with PDE4D7. Results. In univariate analysis, the PDE4D7 score was significantly associated with PSA
recurrence after prostatectomy in both studied patient cohorts’ analysis (HR 0.53; 95% CI 0.41-0.67; p<1.0E-04 and HR 0.47; 95%
CI 0.33-0.65; p<1.0E-04, respectively). After adjustment for the presurgical clinical variables preoperative PSA, PSA density, biopsy
Gleason, clinical stage, percentage tumor in the biopsy (data only available for RP cohort), and percentage of positive biopsies, the
HR was 0.49 (95% CI 0.38-0.64; p<1.0E-04) and 0.43 (95% CI 0.29-0.63; p<1.0E-04), respectively. The addition of the PDE4D7 to
the clinical CAPRA score increased the AUC by 5% over the CAPRA score alone (0.82 versus 0.77; p=0.004). This combination
model stratified 14.6% patients of the DB cohort to no risk of biochemical relapse (NPV 100%) over a follow-up period of up to
15 years. Conclusions. The PDE4D7 score provides independent risk information for pretreatment risk stratification. Combining
CAPRA with PDE4D7 scores significantly improved the clinical risk stratification before surgery.
1. Introduction
Prostate cancer displays as a heterogeneous diseasewith vary-
ing potential to develop progressively to deadly forms of the
disease [1]. Clinically, various schemes for pretreatment risk
classification have been developed based upon longitudinal
biological patient outcomes [2]. While active surveillance
(AS) is recommended by the various guidelines for men
with very low and low risk prostate cancer [3], there is a
significant subgroup in this patient population with a risk
of 10-25% cancer recurrence after primary treatment [4–6].
These patients suffer from the burden of follow-up treatments
that are typically triggered by biochemical relapse. Likewise,
in the intermediate risk group, there is a subpopulation with
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low risk of biochemical progression [7, 8]. Nevertheless,
this group is heterogeneous, comprising patients with varied
outcomes, including those with aggressive pathological char-
acteristics [9, 10].
Clinical risk descriptors do not delineate effectively either
the extent of the disease or its aggressiveness for all patients.
Additionalmolecular information representing the biology of
the disease offers the potential to achieve this.
Cyclic AMP is an ubiquitous second messenger that crit-
ically impacts on the functioning of all cell types in the body
through its effectors, protein kinase A (PKA) and Exchange
Protein Activated by cAMP (Epac) [11, 12]. It has the ability to
regulate independently distinct processes within a single cell
type due to compartmentalisation of signalling processes to
spatially discrete loci (signalosomes) [13, 14].This is achieved
not only by the sequestration of effector molecules and their
targets, but also by the formation and shaping of intracellular
gradients of cyclic AMP by its targeted degradation through
the action of cAMP degrading phosphodiesterases (PDEs)
that are specifically sequestered to distinct signalosomes in
discrete cell locales [14]. Playing a critical role in this are
members of the cAMP specific PDE4 family. Indeed, this
four-gene family (PDE4A/B/C/D), which encodes 20+ iso-
forms, appears to be designed specifically to underpin
compartmentalisation as their isoform-specific N-terminal
regions containmotifs that allow for their targeting to distinct
signalling complexes [15]. Consistent with the importance of
particular PDE4 isoforms, their selective knockdown leads
to distinct phenotypic changes [16] and genetic lesions in
particular PDE4 subfamilies have been shown to provide the
underpinning molecular pathology [17]. PDE4D7 is the so-
called long isoform as it contains both the UCR1 and UCR2
regulatory domains that allow for regulation by various pro-
tein kinases, including PKA and MK2 as well as determining
the functional outcome of catalytic unit phosphorylation by
ERK [14]. Functionally, then it contributes to the cellular
desensitization system towards cAMP and enables cross-talk
between signalling pathways that lead to the activation of
ERK and AMPK.
Recently, we have demonstrated that PDE4D7 transcript
levels correlate to the longitudinal outcome of prostate cancer
and independently add to postsurgical risk stratification in a
consecutively operated prostate cancer patient cohort [18, 19].
To further explore the prognostic power of PDE4D7 in pre-
treatment patient risk assessment, we have investigated here
the correlation to disease recurrence in the context of presur-
gical risk variables and algorithms like the CAPRA (Cancer
of the Prostate Risk Assessment) score. We have developed a
combination model of CAPRA and PDE4D7 scores in a
surgery cohort and validated this model in an independent
patient cohort on diagnostic biopsy tissue. We conclude that
PDE4D7 does not only provide value in postsurgical risk stra-
tification as we have shown before but also increases the stra-
tification power of theCAPRA score in a pretreatment setting.
2. Patients and Methods
2.1. Patient Cohorts and Samples. RP patient cohort (n=550):
patients consecutively managed at a single, large-volume
prostate cancer center were included into the study (Martini-
Klinik, Hamburg, Germany). Two small biopsy punches
(∼1x2 mm) of a representative resected tumor area of patients
operated on between 2000 and 2004 were collected from
the tumors index lesion. Patients who underwent adjuvant
hormone therapy were removed from the study cohort.
RP∗ patient cohort (n=130): detailed characteristics of this
cohort and analysis of the respective gene expression data
were described previously [20]. DB patient cohort (n=168):
from the tumor positive diagnostic biopsy with the highest
Gleason grade per patient a single biopsy punch (∼1x2 mm)
was collected. Patients were diagnosed with prostate cancer
and operated on between 1994 and 2011 at the Prostate
Center (University Hospital Mu¨nster, Germany). After
quality control of the study data based on predefined criteria
[18] 503 and 151 patient samples were defined eligible for
statistical analysis in the RP and the DB cohort, respectively.
The local Institutional Review Boards approved the collection
of patient tissue for clinical research with appropriate patient
consent (for cohort design see Supplementary Figures 3A &
3B).
2.2. Laboratory Methods. To account for potential tumor
heterogeneity, the two tissue punches of the RP cohort
were combined before nucleic acid extraction. A potential
difference in tumor cellularity of the tissue punches was
addressed by normalization of the qPCR results of the
PDE4D transcript to four reference geneswhichwere selected
based on stable gene expression acrossmultiple tumor sample
types [18]. All used molecular laboratory methods including
oligonucleotide primers and probes for RT-qPCR (quantita-
tive real-time PCR), RNA extraction, and quality control and
procedures to include/discard samples from the statistical
analysis were described before [18].
2.3. Data Analysis and Statistics. Generation of normalized
PDE4D transcript expression was performed by subtracting
the Cq of the respective PDE4D transcript from the averaged
Cq of the reference genes. Normalized PDE4D7 expression
was transformed to the PDE4D7 score [19] (Supplementary
Figures 1A & 1B). In correlation analysis for various available
biological and treatment related outcomes (Table 1), the
PDE4D7 score was used either as a continuous or as a
categorical variable defined as (a) PDE4D7 score (1≤2); (b)
PDE4D7 score (>2 and ≤3); (c) PDE4D7 score (>3 and
≤4); (d) PDE4D7 score (>4 and ≤5). The CAPRA risk
score and corresponding low (1), intermediate (2), and high
risk (3) categories were calculated as described earlier [21].
Uni- and multivariate Cox regression and Kaplan-Meier
analyses were applied to correlate biochemical recurrence
(BCR) progression-free survival or secondary treatment (sal-
vage radiation and/or androgen deprivation) free survival
(STFS) to the PDE4D7 score in the RP cohorts (n=503
[18], and Taylor et al. [20] (n=130)) and the DB cohort
(n=151; this study). Decision curve analyses were performed
as described [22]. For statistical analysis, the software package
MedCalc (MedCalc Software BVBA, Ostend, Belgium) was
used. The data analysis strategy is outlined in Supplementary
Figure 2.
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Table 1:Aggregated summary of the characteristics of the studied patient cohorts. (A)Demographics of the radical prostatectomy (RP) patient
cohort including the 503 patients eligible for statistical data analysis. For patient age, preoperative PSA, percentage of tumor in biopsy, prostate
volume, and PSA density themin andmax values in the cohort are shown; median and IQR are depicted in parentheses. Pre- and postsurgical
pathology are given (note: extracapsular extension was derived from pathology stage information). The outcome category illustrates the
cumulative 5- and 10-year biochemical recurrence (BCR) and clinical recurrence to metastases (CR) postsurgical primary treatment. The
treatment category lists the cumulative 5- and 10-year start to SRT (salvage radiation therapy) or SADT (salvage androgen deprivation therapy)
after surgery.Mortality is shown as prostate cancer specific survival (PCSS) aswell as overall survival (OS). (B)Demographics of the diagnostic
biopsy (DB) patient cohort. In total diagnostic needle biopsy tissues of 151 were eligible for statistical data analysis. The demographics and
clinical data of this cohort are presented equivalent to the RP cohort (N/A=not available).
Parameter (A) RP cohort (n=503) (B) DB cohort (n=151)
Demographic & Clinical
Range (median; IQR)
Age range (at RP) 41.3-74.5 (62.6; 7.4) 47.4-77.4 (64.9; 8.5)
Preoperative PSA range 0.18-73.16 (6.7; 5.5) 2.0-49.1 (8.1; 5.7)
Percent tumor in biopsy range 0.2-79.7 (10.3; 16.0) N/A
Prostate Volume range 9-148 (42; 22.5) 13.6-148.0 (38.5; 19.2)
PSA density range 0.01-2.03 (0.16; 0.14) 0.03-1.6 (0.2; 0.17)
CAPRA Risk
Category—No. of patients
(percentage)
Low Risk (NCCN) 211 (41.9%) 38 (25.2%)
Intermediate Risk (NCCN) 248 (49.3%) 82(54.3%)
High Risk (NCCN) 44 (8.7%) 31 (20.5%)
Pre-Surgery
Pathology—Number of
patients (percentage)
Biopsy Gleason 3+3 (GG1) 316 (62.8%) 77 (51.0%)
Biopsy Gleason 3+4 (GG2) 149 (29.6%) 38 (25.2%)
Biopsy Gleason 4+3 (GG3) 25 (5.0%) 20 (13.2%)
Biopsy Gleason >=4+4 (>=GG4) 13 (2.6%) 16 (10.6%)
cT1 342 (68%) 97 (64.2%)
cT2 150 (29.8%)
cT3 11 (2.2%) 54 (35.8%)
Post-Surgery
Pathology—No. of patients
(percentage)
Pathology Gleason 3+3 (GG1) 201 (40%) 46 (30.5%)
Pathology Gleason 3+4 (GG2) 257 (51.1%) 52 (34.4%)
Pathology Gleason 4+3 (GG3) 41 (8.2%) 31 (20.5%)
Pathology Gleason >=4+4 (>=GG4) 4 (0.8%) 22 (14.6%)
pT2 331 (65.8%) 88 (58.3%)
pT3 172 (34.2%) 63 (41.7%)
pT4 0 (0%) 0 (0%)
Positive Surgical Margins 120 (23.9%) 33 (21.9%)
Capsular Status 113 (22.5%) (=T3a) 57/145 (39.3%) infiltrated;75/145 (51.7%) penetrated
Positive Seminal Vesicle Invasion 60 (11.9%) 20 (13.2%)
Positive Lymph Node Invasion 5 (1%) 10 (6.6%)
Follow-up [months] (IQR
median follow-up)
Mean 123.6 73.7
Median 141.8 73.6
Outcome—No events /
total patient number
(percentage; median
follow-up; IQR)
BCR within 5 years 92/446 (20.6%; 121.2; 87.5) 49/151 (32.5%; 73.7; 43.9)
BCR within 10 years 134/347 (38.6%; 134.0; 95.6) N/A
CR within 5 years 5/441 (1.1%; 144.4; 37.8) 4/151 (2.6%; 73.7; 42.6)
CR within 10 years 13/306 (4.2%; 154.7; 32.85) N/A
Salvageerapy—No
events / total patient
number (percentage;
median follow-up; IQR)
SRT within 5 years 53/439 (12.1%; 120.4; 53.5) 12/151 (7.9%; N/A; N/A)
SRT within 10 years 83/320 (25.9%; 132.3; 39.6) N/A
SADT within 5 years 27/441 (6.1%; 120.7; 46.6) 16/151 (10.6%; N/A; N/A)
SADT within 10 years 54/312 (17.3%; 132.4; 24.2) N/A
Survival—No events / total
patient number
(percentage; median
follow-up; IQR)
PCSS within 5 years 17/453 (1.1%; 144.4; 37.7) 1/151 (0.7%; N/A; N/A)
PCSS within 10 years 38/330 (2.6%; 154.8; 30.3) 0/151 (0%; N/A; N/A)
OS within 5 years 5/441 (3.7%; 144.4; 45.1) 1/151 (0.7%; N/A; N/A)
OS within 10 years 10/302 (11.2%; 146.0; 35.4) 5/151 (3.3%; N/A; N/A)
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3. Results
3.1. Correlation of PDE4D7 Score to Longitudinal Clinical
Outcomes. We recently described the association of the
expression of the prostate cancer biomarker PDE4D7 to
postsurgical biochemical relapse based on the quantitation of
the PDE4D transcript in surgical resection tissues [18]. Here
we set out to translate this earlier finding to a presurgical
setting using three independent patient cohorts. Firstly, we
evaluated a radical prostatectomy (RP) cohort comprising
550 patients (Supplementary Figure 3A) [18]. In this patient
cohort, a logistic regression model of the PDE4D7 score
together with the presurgical CAPRA risk score was devel-
oped to predict the risk of postsurgical BCR. Secondly, we
tested this PDE4D7 & CAPRA risk model for BCR outcome
in an independent surgery cohort (RP∗; n=130 [20]). It is well
known that >30% of tumors with an initial biopsy Gleason
3+3 undergo grade migration to a pathology Gleason 3+4
after surgery; we could confirm this effect in the RP cohort
used in this study while any other stage migration with initial
biopsy Gleason scores >3+3 was much less frequent (<5%).
However, we could not find a significant PDE4D7 expression
difference in tumors that were upgraded postsurgically from
a biopsyGleason 3+3 to a pathologyGleason 3+4 versus those
tumors that remained Gleason 3+3 after radical prostatec-
tomy (data not shown). Therefore, we hypothesized that the
association of PDE4D7 measured on resection tissue with
presurgical clinical variables will translate into equivalent
results on preoperatively prostate needle biopsy tissue. To
test this hypothesis, we validated the PDE4D7 & CAPRA
riskmodel to predict postoperative BCRwhich we developed
using the RP cohort in a presurgical needle biopsy (DB)
cohort. This cohort comprised 168 patients of which 151 were
eligible for subsequent data analysis (Table 1; Supplementary
Figure 3B).
Univariate Cox regression analysis demonstrated a very
significant association of the continuous PDE4D7 score to
time to BCR in the RP and DB patient cohorts with HR=0.53;
95% CI=0.41-0.67; p<0.0001, and HR=0.47; 95% CI=0.33-
0.65, p=<0.0001, respectively. Adjusting the multivariate Cox
regression analysis for the presurgical variables age, preoper-
ative PSA, PSA density, biopsy Gleason grade group, percent
tumor positive biopsy cores, clinical stage, or the prognostic
CAPRA score [21] resulted in a significant independent
contribution to the prediction of postsurgical BCR for the
continuous PDE4D7 score (Tables 2(a), 2(b)).
3.2. Outcome Modeling of Combined CAPRA and PDE4D7
Scores. To explore this further we set out to test the benefit
of a combination of the PDE4D7 score with clinical variables
used to predict postsurgical risk of disease progression. Based
on our multivariate Cox regression data we hypothesized
that a combination of the CAPRA score, together with the
PDE4D7 score, might provide a significant improvement in
prognostic power over the CAPRA score alone. The CAPRA
algorithm combines age, preoperative PSA, biopsy Gleason,
and percent of tumor positive biopsy cores. The resulting
score categorized patients into low risk (CAPRA scores 0-2),
intermediate risk (CAPRA scores 3-5), and high risk (CAPRA
scores 6-10). The CAPRA score has been shown to predict,
significantly, postsurgical PSA relapse in several studies [23].
To evaluate our postulation we selected a subcohort of 449
patients (92 events; 20.5%) of the RP cohort with complete
5-year outcome histories and generated a logistic regression
model to combine PDE4D7 with the CAPRA score so as
to predict the 5-year risk of biochemical recurrence after
surgery (odds ratio 0.46; 95% CI 0.3-0.69; p=0.0002; data not
shown).Next, we tested this CAPRA&PDE4D7 score logistic
regression model on 130 patients from the independent RP∗
cohort [20] as well as on the 151 patients of the DB cohort for
Kaplan-Meier survival analysis and ROC curve analysis, as
well as decision curve analysis (see Supplementary Figure 2
for data analysis strategy).
In Kaplan-Meier survival studies on the DB patient
cohort, we observed a significant separation of patients into
different risks to experience postoperative PSA relapse based
on the presurgical measurement of the PDE4D7 score in a
tissue punch of a diagnostic needle biopsy (Figure 1(a)). We
then compared postsurgical progression-free survival curves
of the three CAPRA score categories (low, intermediate,
and high risk) with progression-free survival based on the
CAPRA&PDE4D7 logistic regression combinationmodel in
theDB (n=151) patient cohort. Concerning the logistic regres-
sion model we categorized the model-calculated risk prob-
ability to experience the clinical endpoint into four groups
(p<0.1; p=0.1 to <0.25; p=0.25 to <0.5; p=0.5 to 1.0) and
compared the hazard ratio (HR) difference between the low-
est versus highest recurrence risk groups between the tested
models (Figures 1(b) and 1(c)). The addition of the PDE4D7
score to the clinical CAPRA categories proved to significantly
increase in the hazard ratio difference from the lowest to the
highest risk group in the DB cohort (HR=9.0 for the CAPRA
score; HR for the CAPRA & PDE4D7 combination score
could not be determined due to no event in the lowest risk
group which is used as the reference; Figures 1(b) and 1(c)).
We then set out to test the clinically relevant endpoint
of secondary treatment free survival (STFS). This endpoint
comprises start of any salvage therapy (radiation, hormone
ablation) after postsurgical PSA failure. As before, we noticed
an improved risk separation between patients with lowest
versus highest risk groups to receive postsurgical secondary
treatment when combining the CAPRA with PDE4D7 scores
versus CAPRA score categories alone (Figures 1(d)–1(f)).
Finally, we confirmed the performance of the CAPRA &
PDE4D7 combination model versus the CAPRA score cat-
egories on the RP∗ cohort (HR=11.8 for CAPRA score versus
HR=16.4 for the CAPRA & PDE4D7 combination score,
respectively (Supplementary Figures 4A & 4B)).
Next, we analysed the prediction of risk of 5-year PSA
relapse after primary treatment using the CAPRA score alone
versus the CAPRA & PDE4D7 score combination model,
whichwas previously developed using the RP cohort. In ROC
analysis, we calculated the 5-year BCR AUCs as 0.77 for the
CAPRA score alone and 0.82 for the combination model
of CAPRA & PDE4D7 score model (p=0.004; Figure 2(a)).
Further, the CAPRA & PDE4D7 combination model showed
equivalent performance in a subcohort analysis includ-
ing only patients with biopsy Gleason ≥7 over CAPRA
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Figure 1: Continued.
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Figure 1: Kaplan-Meier survival analysis of the time to PSA relapse (endpoint: BCR) or start of any salvage therapy after radical prostatectomy
(endpoint: STFS) in the DB patient cohort (n=151). ((a)-(c)) Kaplan-Meier analysis of the biochemical recurrence (BCR) free survival in the
patient diagnostic biopsy (DB) cohort of the categorized PDE4D7 score, the CAPRA score categories, and the CAPRA & PDE4D7 score
combinationmodel. ((d)-(f))Kaplan-Meier analysis of postsurgical secondary treatment free survival (STFS) in the patient diagnostic biopsy
(DB) cohort of the categorized PDE4D7 score, the CAPRA score categories, and the CAPRA & PDE4D7 score combination model. The
CAPRA & PDE4D7 combination model was developed by logistic regression in the RP patient cohort and used as such for testing in the DB
patient cohort. Censored patients are indicated by vertical bars. PDE4D7 score categories were defined as PDE4D7 (1-2): PDE4D7 scores (1
to <2); PDE4D7 (2-3): PDE4D7 scores (2 to <3); PDE4D7 (3-4): PDE4D7 scores (3 to <4); PDE4D7 (4-5): PDE4D7 scores (4 to <=5). The
CAPRA score categories were defined as CAPRA (1): CAPRA scores 0-2; CAPRA (2): CAPRA scores 3-5; CAPRA (3): CAPRA scores ≥6.The
CAPRA & PDE4D7 score categories were defined according to the probability to experience PSA failure after surgery based on the logit(p)
function of the logistic regression model. Four categories of probabilities were selected: p<0.1; p=0.1 to <0.25; p=0.25 to <0.5; p=0.5 to 1.0 to
risk categorize the DB patients.
score alone (AUC=0.8 versus 0.73, respectively; Figure 2(b);
p=0.026).This datamay indicate an improved discrimination
performance of the combination model in patients with
higher risk characteristics.
Recently, the concept of decision curve analysis (DCA)
was introduced to test the value of a biomarker or prediction
model in clinical practice [24]. DCA is a net benefit analysis,
which compares the true-positive to the weighted false-
positive rates across different risk thresholds. We explored
the net benefit of avoiding primary treatment based on the
predicted risk of a PSA relapse after surgery for the CAPRA
score, and the CAPRA & PDE4D7 combination model.
The analysis demonstrated that the two models showed
better net benefit compared to the “treat all” strategy while
the combined CAPRA & PDE4D7 score revealed the best
net benefit across all modeled decision thresholds (0-50%;
Figure 3(a)). Similarly, the net reduction analysis in primary
treatment based on the two tested decision models revealed
a substantial difference in treatment reduction between the
CARPA score and the CARPA & PDE4D7 combination
model with decision thresholds ≤30% (Figure 3(b)). At
higher decision thresholds above 30% the CAPRA score
might perform equivalent to the CAPRA & PDE4D7 score.
However, it seems questionable whether such thresholds of
30% and higher risk of disease recurrence and progression
are of any practical relevance for a patient to avoid a primary
treatment like surgery.
We have illustrated that a predictive model of the clinical
risk algorithm CAPRA with the prostate cancer biomarker
PDE4D7 in a diagnostic needle biopsy sample provides value
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Figure 2: (a) ROC curve analysis of 5-year biochemical recurrence (BCR) in the DB cohort (n=151) of the CAPRAP score versus the CAPRA
& PDE4D7 logistic regression model which was developed on the RP patient cohort with complete 5-year follow-up (n=449). (b) Subcohort
ROC curve analysis of the 5-year biochemical recurrence (BCR) of CAPRA & PDE4D7 logistic regression model compared to the CAPRA
model alone. In this analysis, only patients with a biopsy Gleason ≥7 were included (n=74).
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Figure 3: (a) Decision curve analysis in the diagnostic biopsy (DB) patient cohort of the net benefit of four different treatment decision
strategies for men at risk of disease recurrence within 5 years after surgery. In total 45 of the 151 investigated patients failed the initial primary
treatment of surgery by PSA recurrence (29.8%) within 5 years after intervention. Treatment strategies were tested for their net benefit across
indicated threshold probabilities (0.05 step size) to trigger prostate surgery based on the probability of future disease recurrence.The CAPRA
scores and the CAPRA& PDE4D7 scores were converted into 5-year BCR probabilities with logistic regression on the RP cohort (n=449men
with completed 5-year follow-up) before estimating net benefit. (b) Net reduction analyses demonstrating in how many patients a resection
can be avoided based on the predicted risk of BCR derived from the CAPRA score and CAPRA & PDE4D7 score model, respectively.
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to risk stratification. We have demonstrated in multiple
analyses that this risk prediction model performs better in
stratifying prostate cancer patients to treatment relevant risk
categories compared to risk schemas solely based on clinical
parameters.
4. Discussion
Recently, we have reported the association of the PDE4D7
score to postsurgical disease recurrence in a radical prosta-
tectomy (RP) patient cohort. Here we aimed to demonstrate
that a logistic regression model developed on the same RP
cohort using the preclinical risk score CAPRA with the
PDE4D7 score remains its prognostic power in diagnostic
needle biopsy (DB) patients. Thus, we were able to confirm
the associated hazard ratio (∼0.5 per score unit change) in
this DB cohort to predict biochemical failure after surgery
in the same order of magnitude as shown on surgical tumor
tissue.We conclude that the associated hazard of the PDE4D7
score is stable across independent patient cohorts as well as in
different tissue collection settings (diagnostic biopsies versus
surgical resections).
Treatment decisions in primary, localized prostate cancer
are largely subject to a combination of the risk of future
disease progression and life expectancy. The National Com-
prehensive Cancer Network (NCCN) has defined six risk cat-
egories based on pretreatment clinical variables [3]. Depend-
ing on the clinical risk various options of interventions are
presented in the guidelines. Multiple tools of clinical risk
prediction have been developed in the form of mathematical
models, which combine the value of clinical variables into
a single score [25]. One of the most extensively validated
clinical risk algorithms for pretreatment decision support is
the CAPRA score [21].The score is a combination of clinically
available information. Originally reported in 2005, this score
has been validated in several studies since then [23]. Our data
illustrate that the PDE4D7 score adds important prognostic
value to clinical predictionmodels, such as the CAPRA score,
for disease-specific outcomes to support treatment decision-
making.
Recently, the long-term results of the active surveillance
cohort within the Go¨teborg randomized prostate cancer
screening trial were published [26]. This data indicated that
men with clinically low risk disease may have a considerable
risk to experience progressive disease under a deferred
treatment regime.Therefore, the authors questioned whether
men other than those with very low risk disease would
be eligible for expectant management strategies. The recent
publication of the 10-year outcomes of the ProtecT study
indicates similar conclusions in the active monitoring arm of
the trial [27]. Although there is some debate about the validity
of these results to contemporary practice [28] they suggest
that only patients with the very lowest risk are safe of any
progression during deferred treatment management. While
the use of clinical criteria like CAPRA allow the selection
of such a low risk patient cohort the addition of molecular
markers can be expected to enlarge this very low risk patient
group or further reduce the risk within this cohort. In fact,
our combined CAPRA & PDE4D7 regression model defines
a very low risk cohort of 22 out of 151 patients (14.6%) in the
DB patient cohort with a progression-free survival (PFS) of
100% over a follow-up period ofmore than 15 years compared
to a PFS of 85.6% for the CAPRA score alone.
Active surveillance (AS) has been established as a safe
treatment alternative for men with low risk prostate cancer
over the last years [29]. However, the challenge associated
with AS relates to the strict monitoring schedules that men
are advised to follow in order not to miss signs of progressive
disease. These include the identification of elevations in PSA
and upgrading of biopsy Gleason scores, which are typically
”protocol triggers” to switch from AS to active treatment.
Longitudinal AS studies have published decreasing patient
compliance to the monitoring protocols in AS over time in
particular when it comes to additional biopsy procedures
[30, 31]. This issue might be addressed with a selection algo-
rithm such as that proposed here, i.e., the combination of
the CAPRA score with the prognostic genomic biomarker
PDE4D7, in order to define a patient cohort with virtually no
risk of future disease progression. Although this finding has
to be confirmed in anAS setting, thismight provide away for-
ward to include men into active surveillance on the basis of
very limited (or no) follow-up for a given time period after
the initiation of AS.
4.1. Limitations. A potential limitation of this study might
be the sample size of the diagnostic biopsy cohort used
for the CAPRA & PDE4D7 model validation. However,
the measured endpoints of BCR and of secondary treat-
ment start provide a relevant number of events (36.4% and
19.9%, respectively) for validation testing. Nevertheless, we
appreciate the fact that further validation of this model
is required which is warranted by the so far presented
results. Another limitation might be in the selection of BCR
(biochemical recurrence) as a tested endpoint. The follow-
up of the diagnostic biopsy cohort was too limited to enable
the testing for clinical recurrence or prostate cancer death.
However, to our opinion, BCR is still a treatment relevant
endpoint and is used as a decision point to a start secondary
treatment in a majority of the patients (e.g., in 73.2% of
patients in the RP cohort who experienced BCR a secondary
treatment was started). Furthermore, PSA progression is also
a typical protocol-based trigger to stop active surveillance
and initiate an active intervention. Ultimately, we believe
that it is important to understand the risk to experience this
endpoint for an optimal treatment decision.
5. Conclusions
With the data presented here we have further validated the
prognostic power of the prostate cancer biomarker PDE4D7.
We have demonstrated that the PDE4D7 score has equiv-
alent performance to predict longitudinal prostate cancer
outcomes when tested on tumor tissue of a diagnostic biopsy
sample compared to a cancer sample that was collected after
prostate resection during surgery. This study illustrates the
potential of PDE4D7 for clinical use to improve presurgical
risk stratification in conjunction with the routinely used
prognostic clinical risk models.
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Table 2: Uni- and multivariate Cox regression analysis of biochemical recurrence (BCR) free survival and overall survival (OS) of the
continuous PDE4D7 scores. In multivariate analysis, the PDE4D7 scores were adjusted by presurgical clinical variables or the CAPRA score
as indicated. Biopsy Gleason and pathology stage were modeled as categories. All other demographic and clinical variables as well as the
PDE4D7 scores were modeled as continuous variables. All variables were entered into the multivariate modeling. (a) Uni- and multivariate
Cox regression analysis of the biochemical recurrence (BCR) free survival of the PDE4D7 score in the RP study cohort (n=503; 148 (29.4%)
events); multivariate analysis was adjusted for presurgical variables or CAPRA scores. (b) Uni- and multivariate Cox regression analysis of
the biochemical recurrence (BCR) free survival of the PDE4D7 score in the DB study cohort (n=151; 55 (36.4%) events); multivariate analysis
was adjusted for presurgical variables or CAPRA scores. PDE4D7 score categories were defined as PDE4D7 (1-2): PDE4D7 scores (1 to <2);
PDE4D7 (2-3): PDE4D7 scores (2 to <3); PDE4D7 (3-4): PDE4D7 scores (3 to <4); PDE4D7 (4-5): PDE4D7 scores (4 to <=5).
(a)
Pre-Surgical Clinical Parameters univariate multivariate
Endpoint BCR (#148/#503; 29.4%) p value HR 95% CI of HR p value HR 95% CI of HR
Age at surgery 0,88 1,0 0.97 -1.03 0,77 1,00 0.96 to 1.02
Preoperative PSA 0,0002 1,03 1.01-1.04 0,00 1,08 1.03 to 1.1
PSA density 0,0100 2,15 1.2 to 3.8 0,03 0,12 0.02 to 0.8
Biopsy Gleason Score 3+3 (N=316); reference
Biopsy Gleason Score 3+4 (N=149) 0,0003 1,9 1.4-2.8 0,02 1,56 1.06 to 2.3
Biopsy Gleason Score >=4+3 (N=38) <0.0001 6,2 3.9-9.7 <0.0001 4,82 2.9 to 7.9
Percentage Positive Biopsy Cores <0.0001 4,2 2.3-7.7 0,08 2,29 0.91 to 5.7
Percentage Tumor in Biopsy <0.0001 1,0 1.02-1.04 0,00 1,02 1.01 to 1.04
Clinical stage cT1c (N= 342); reference
Clinical stages cT2 & cT3 (N=161) <0.0001 2,1 1.5 to 2.9 0,20 1,27 0.88 to 1.8
PDE4D7 (continuous) <0.0001 0,53 0.41 to 0.67 <0.0001 0,52 0.4 to 0.68
Pre-Surgical Clinical Parameters univariate multivariate
Endpoint BCR (#148/#503; 29.4%) p value HR 95% CI of HR p value HR 95% CI of HR
CAPRA Score <0.0001 1,5 1.3 to 1.6 <0.0001 1,7 1.5 to 1.9
PDE4D7 (continuous) <0.0001 0,47 0.33 to 0.65 <0.0001 0,56 0.43 to 0.72
(b)
Pre-Surgical Clinical Parameters univariate multivariate
Endpoint BCR (#55/#151; 36.4%) p value HR 95% CI of HR p value HR 95% CI of HR
Age at surgery 0,81 0,99 0.95 to 1.04 0,006 0,94 0.89 to 0.98
Preoperative PSA 0,0001 1,04 1.02 to 1.06 0,002 1,1 1.03 to 1.2
PSA Density 0,003 2,7 1.4 to 5.3 0,18 0,26 0.04 to 1.9
Biopsy Gleason GG1 (n=85); reference
Biopsy Gleason GG2 (n=44) 0,07 1,9 0.95 to 3.8 0,10 1,9 0.89 to 3.9
Biopsy Gleason GG3 (n=20) 0,0001 4,3 2.04 to 9.2 0,02 2,6 1.2 to 5.7
Biopsy Gleason GG4 (n=7) 0,0007 5,7 2.1 to 15.8 0,01 4,1 1.4 to 11.6
Biopsy Gleason GG5 (n=11) <0.0001 8,0 3.5 to 18.4 0,03 2,9 1.1 to 7.6
Percentage Positive Biopsy Cores 0,013 4,6 1.4 to 15.2 0,19 2,4 0.63 to 9.4
Clinical stage cT2 (n= 108); reference
Clinical stage cT3 (n=60) 0,007 2,0 1.2 to 3.4 0,05 1,7 0.99 to 3.1
PDE4D7 (continuous) <0.0001 0,47 0.33 to 0.65 <0.0001 0,43 0.29 to 0.63
Pre-Surgical Clinical Parameters univariate multivariate
Endpoint BCR (#55/#151; 36.4%) p value HR 95% CI of HR p value HR 95% CI of HR
CAPRA Score <0.0001 1,5 1.3 to 1.6 <0.0001 1,4 1.2 to 1.6
PDE4D7 (continuous) <0.0001 0,47 0.33 to 0.65 0,0001 0,53 0.38 to 0.74
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RP: Radical prostatectomy
DB: Diagnostic biopsy
BCR: Biochemical recurrence
STFS: Secondary treatment free survival
HR: Hazard ratio
CI: Confidence interval
NPV: Negative predictive value
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DCA: Decision curve analysis
CAPRA score: Cancer of the Prostate Risk Assessment
score.
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